New Study Says I Was Wrong About NMN and NR?

Key Takeaways

• Small study favors NR; larger trial shows parity
• Gut microbes convert NR/NMN to nicotinic acid
• NAD rise does not equal functional improvements
• Exercise outperforms supplements for NAD support
• Premium pricing may be unjustified

Pulse Analysis

NAD (nicotinamide adenine dinucleotide) is a central coenzyme that fuels cellular metabolism, DNA repair, and signaling pathways. As people age, NAD levels tend to decline, prompting a multibillion‑dollar market for oral precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). Both molecules are marketed as premium forms of vitamin B3 that can directly replenish intracellular NAD, and they have attracted high‑profile backers from academia and biotech. The promise of a simple pill that slows aging has driven aggressive branding, price premiums, and a fierce rivalry between the two camps.

New human data are reshaping that narrative. A small Norwegian crossover trial reported a 2.3‑fold greater NAD increase with NR versus NMN, but a subsequent 65‑subject, double‑blind study published in Nature Metabolism found no statistical difference; both compounds roughly doubled circulating NAD after two weeks. Parallel mechanistic work shows that oral NR and NMN are largely broken down by gut microbes into nicotinic acid, which then re‑enters NAD synthesis via the Preiss‑Handler pathway. This microbial conversion means the two supplements converge on the same inexpensive B3 route, undermining the claim that one is a superior, more bioavailable precursor.

Despite consistent NAD elevation, clinical outcomes remain elusive. Meta‑analyses of randomized trials in older adults reveal no significant gains in muscle strength, gait speed, or metabolic markers, and a long‑COVID study found NR failed to improve fatigue or mood despite a three‑fold NAD rise. Meanwhile, exercise training naturally restores muscle NAD to youthful levels without supplementation, highlighting lifestyle as a more reliable strategy. For consumers and investors, the emerging evidence suggests that the premium pricing of NR and NMN may be hard to justify until robust efficacy data emerge, and that the broader anti‑aging narrative should focus on proven interventions rather than unproven vitamin analogues.